Skip to main content

Advertisement

Log in

Correlation of hormone receptor status between circulating tumor cells, primary tumor, and metastasis in breast cancer patients

  • Research Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Purpose

Estrogen receptor (ER) and progesterone receptor (PR) status is prognostic and predictive in breast cancer. Because metastatic breast tumor biopsies are not routinely feasible, circulating tumor cells (CTCs) offer an alternative source of determining ER/PR tumor status.

Methods/patients

Peripheral blood was collected prospectively from 36 patients with metastatic breast cancer. CTCs were isolated using the microfluidic OncoCEE™ platform. Detection was accomplished with an expanded anti-cytokeratin (CK) cocktail mixture and anti-CD45. ER/PR protein expression was assessed by immunocytochemistry (ICC) on the CK+ cells and compared to the primary and/or metastatic tumor by immunohistochemistry (IHC).

Results

Among the 24 CK + CTC cases, a concordance of 68 % (15/22) in ER/PR status between primary breast tumor and CTCs and 83 % (10/12) between metastatic tumor and CTCs was observed. An overall concordance of 79 % (19/24) was achieved when assessing CTC and metastatic tumor (primary tumor substituted if metastatic breast biopsy not available). A test sensitivity of 72 % and specificity of 100 % was identified when comparing CTCs to tumor tissue. Of the 7 discordant cases between CTCs and primary tumor tissue, 2 were concordant with the metastatic biopsy.

Conclusions

CTC ER/PR status using the OncoCEE™ platform is feasible, with high concordance in ER/PR status between tumor tissue (IHC) and CTCs (ICC). The prognostic and predictive significance of CTC ER/PR protein expression needs further evaluation in larger trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Sieuwerts AM, Mostert B, Bolt-de Vries J, Peeters D, de Jongh FE, Stouthard JML. mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients. Clin Cancer Res. 2011;17(11):3600–18. doi:10.1158/1078-0432.ccr-11-0255.

    Article  CAS  PubMed  Google Scholar 

  2. Cleator SJ, Ahamed E, Coombes RC, Palmieri C. A 2009 update on the treatment of patients with hormone receptor-positive breast cancer. Clin Breast Cancer. 2009;9(Suppl 1):S6–17. doi:10.3816/CBC.2009.s.001 G44434VK149RM452.

    Article  CAS  PubMed  Google Scholar 

  3. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American society of clinical oncology/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010;134(7):e48–72. doi:10.1043/1543-2165-134.7.e48.

    CAS  PubMed  Google Scholar 

  4. Lower EE, Glass EL, Bradley DA, Blau R, Heffelfinger S. Impact of metastatic estrogen receptor and progesterone receptor status on survival. Breast Cancer Res Treat. 2005;90(1):65–70. doi:10.1007/s10549-004-2756-z.

    Article  CAS  PubMed  Google Scholar 

  5. Liedtke C, Broglio K, Moulder S, Hsu L, Kau SW, Symmans WF, et al. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol. 2009;20(12):1953–8. doi:10.1093/annonc/mdp263 mdp263.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Aitken SJ, Thomas JS, Langdon SP, Harrison DJ, Faratian D. Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases. Ann Oncol. 2010;21(6):1254–61. doi:10.1093/annonc/mdp427 mdp427.

    Article  CAS  PubMed  Google Scholar 

  7. Simmons C, Miller N, Geddie W, Gianfelice D, Oldfield M, Dranitsaris G, et al. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann Oncol. 2009;20(9):1499–504. doi:10.1093/annonc/mdp028 mdp028.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Amir E, Miller N, Geddie W, Freedman O, Kassam F, Simmons C, et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol. 2012;30(6):587–92. doi:10.1200/jco.2010.33.5232.

    Article  PubMed  Google Scholar 

  9. Fehm T, Muller V, Aktas B, Janni W, Schneeweiss A, Stickeler E, et al. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Res Treat. 2010;124(2):403–12. doi:10.1007/s10549-010-1163-x.

    Article  CAS  PubMed  Google Scholar 

  10. Liu MC, Shields PG, Warren RD, Cohen P, Wilkinson M, Ottaviano YL, et al. Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. J Clin Oncol. 2009;27(31):5153–9. doi:10.1200/jco.2008.20.6664.

    Article  PubMed  Google Scholar 

  11. Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res. 2006;12(14 Pt 1):4218–24. doi:10.1158/1078-0432.CCR-05-2821 12/14/4218.

    Article  CAS  PubMed  Google Scholar 

  12. Aktas B, Muller V, Tewes M, Zeitz J, Kasimir-Bauer S, Loehberg CR, et al. Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients. Gynecol Oncol. 2011;122(2):356–60. doi:10.1016/j.ygyno.2011.04.039 S0090-8258(11)00340-4.

    Article  CAS  PubMed  Google Scholar 

  13. Somlo G, Lau SK, Frankel P, Hsieh HB, Liu X, Yang L, et al. Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology. Breast Cancer Res Treat. 2011;128(1):155–63. doi:10.1007/s10549-011-1508-0.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  14. Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 2007;450(7173):1235–9. doi:10.1038/nature06385 nature06385.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  15. Paterlini-Brechot P, Benali NL. Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett. 2007;253(2):180–204. doi:10.1016/j.canlet.2006.12.014 S0304-3835(06)00686-0.

    Article  CAS  PubMed  Google Scholar 

  16. Mayer JA, Pham T, Wong KL, Scoggin J, Sales EV, Clarin T, et al. FISH-based determination of HER2 status in circulating tumor cells isolated with the microfluidic CEE platform. Cancer Genet. 2011;204(11):589–95. doi:10.1016/j.cancergen.2011.10.011 S2210-7762(11)00304-8.

    Article  CAS  PubMed  Google Scholar 

  17. Dickson MN, Tsinberg P, Tang Z, Bischoff FZ, Wilson T, Leonard EF. Efficient capture of circulating tumor cells with a novel immunocytochemical microfluidic device. Biomicrofluidics. 2011;5:034119.

    Article  Google Scholar 

  18. Pecot CV, Bischoff FZ, Mayer JA, Wong KL, Pham T, Bottsford-Miller J, et al. A novel platform for detection of CK+ and CK − CTCs. Cancer Discov. 2011;1(7):580–6. doi:10.1158/2159-8290.CD-11-0215 2159-8290.CD-11-0215.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  19. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159–74.

    Article  CAS  PubMed  Google Scholar 

  20. Hollestelle A, Nagel JH, Smid M, Lam S, Elstrodt F, Wasielewski M, et al. Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines. Breast Cancer Res Treat. 2010;121(1):53–64. doi:10.1007/s10549-009-0460-8.

    Article  PubMed  Google Scholar 

  21. Fehm T, Hoffmann O, Aktas B, Becker S, Solomayer EF, Wallwiener D, et al. Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Res. 2009;11(4):R59. doi:10.1186/bcr2349 bcr2349.

    Article  PubMed Central  PubMed  Google Scholar 

  22. Nadal R, Fernandez A, Sanchez-Rovira P, Salido M, Rodriguez M, Garcia-Puche JL, et al. Biomarkers characterization of circulating tumour cells in breast cancer patients. Breast Cancer Res. 2012;14(3):R71. doi:10.1186/bcr3180 bcr3180.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Babayan A, Hannemann J, Spötter J, Müller V, Pantel K, Joosse SA. Heterogeneity of estrogen receptor expression in circulating tumor cells from metastatic breast cancer patients. PLoS One. 2013;8(9):e75038. doi:10.1371/journal.pone.0075038.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgments

The authors wish to thank all of the employees at Biocept and the following laboratory personnel for the work and dedication to this project: Mark Tong, Maryam Zomorrodi, Lisa Strauser, Valeriya Prozorovska, Ronnie Spielvogel, Leticia Flores, Christine Mitchell, Margaret Jeffrey, Andrew Nguyen, Jana Salvacion, and Ferdinand Banez. In addition, the authors would also like to thank Drs. Dawn Hershman, MD, MS and Katherine Crew, MD, MS for their support and accrual of patients to this study. This publication was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant Number KL2 TR000081 and the Witten Breast Cancer Research Fund. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Conflict of interest

F. Z. Bischoff, J. A. Mayer, T. Pham, K. L. Wong, E. Villarin, and T. J. Pircher, are presently or were previously employees of Biocept Incorporated. None of the other contributors have any potential conflicts of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to K. Kalinsky.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kalinsky, K., Mayer, J.A., Xu, X. et al. Correlation of hormone receptor status between circulating tumor cells, primary tumor, and metastasis in breast cancer patients. Clin Transl Oncol 17, 539–546 (2015). https://doi.org/10.1007/s12094-015-1275-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-015-1275-1

Keywords

Navigation